Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
26.27
-0.53 (-1.98%)
At close: Apr 28, 2026, 4:00 PM EDT
26.39
+0.12 (0.44%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Forte Biosciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Forte Biosciences stock have an average target of 67, with a low estimate of 61 and a high estimate of 75. The average target predicts an increase of 155.04% from the current stock price of 26.27.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 25, 2025.
Analyst Ratings
The average analyst rating for Forte Biosciences stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $65 | Buy | Initiates | $65 | +147.43% | Nov 25, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $61 | Strong Buy | Maintains | $61 | +132.20% | Nov 17, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $75 | Strong Buy | Initiates | $75 | +185.50% | Aug 18, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $61 | Strong Buy | Maintains | $61 | +132.20% | Aug 15, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $61 | Strong Buy | Maintains | $61 | +132.20% | Jun 24, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.20
from -4.71
EPS Next Year
-4.43
from -4.20
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.86 | -2.39 | ||||||
| Avg | -4.20 | -4.43 | ||||||
| Low | -4.75 | -5.77 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.